These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

502 related articles for article (PubMed ID: 33709856)

  • 1. Efficacy and Safety of Inhaled Glycopyrronium Bromide in COPD: A Randomized, Parallel Group, Dose-Ranging Study (GLIMMER).
    Kerwin E; Feldman G; Pearle J; De La Cruz L; Edwards M; Beaudot C; Georges G
    COPD; 2021 Apr; 18(2):181-190. PubMed ID: 33709856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bronchodilator efficacy of extrafine glycopyrronium bromide: the Glyco 2 study.
    Singh D; Scuri M; Collarini S; Vezzoli S; Mariotti F; Muraro A; Acerbi D
    Int J Chron Obstruct Pulmon Dis; 2017; 12():2001-2014. PubMed ID: 28744115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The bronchodilator effects of extrafine glycopyrronium added to combination treatment with beclometasone dipropionate plus formoterol in COPD: A randomised crossover study (the TRIDENT study).
    Singh D; Schröder-Babo W; Cohuet G; Muraro A; Bonnet-Gonod F; Petruzzelli S; Hoffmann M; Siergiejko Z;
    Respir Med; 2016 May; 114():84-90. PubMed ID: 27109816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial.
    Vestbo J; Papi A; Corradi M; Blazhko V; Montagna I; Francisco C; Cohuet G; Vezzoli S; Scuri M; Singh D
    Lancet; 2017 May; 389(10082):1919-1929. PubMed ID: 28385353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial.
    Singh D; Papi A; Corradi M; Pavlišová I; Montagna I; Francisco C; Cohuet G; Vezzoli S; Scuri M; Vestbo J
    Lancet; 2016 Sep; 388(10048):963-73. PubMed ID: 27598678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β
    Ferguson GT; Darken P; Ballal S; Siddiqui MK; Singh B; Attri S; Holmgren U; de Nigris E
    Adv Ther; 2020 Jun; 37(6):2956-2975. PubMed ID: 32335859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study.
    Buhl R; Gessner C; Schuermann W; Foerster K; Sieder C; Hiltl S; Korn S
    Thorax; 2015 Apr; 70(4):311-9. PubMed ID: 25677679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel model-based approach for dose determination of glycopyrronium bromide in COPD.
    Arievich H; Overend T; Renard D; Gibbs M; Alagappan V; Looby M; Banerji D
    BMC Pulm Med; 2012 Dec; 12():74. PubMed ID: 23217058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose-response of an extrafine dry powder inhaler formulation of glycopyrronium bromide: randomized, double-blind, placebo-controlled, dose-ranging study (GlycoNEXT).
    Beeh KM; Emirova A; Prunier H; Santoro D; Nandeuil MA
    Int J Chron Obstruct Pulmon Dis; 2018; 13():1701-1711. PubMed ID: 29872288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ethnic Sensitivity Study of the Extrafine, Single-Inhaler, Triple Therapy Beclomethasone Dipropionate, Formoterol Fumarate, and Glycopyrronium Bromide Pressurized Metered Dose Inhaler in Japanese and Caucasian Healthy Individuals: A Randomized, Double-Blind, Single-Dose Crossover Study.
    Cella M; Täubel J; Delestre-Levai I; Tulard A; Vele A; Georges G
    Clin Ther; 2021 Nov; 43(11):1934-1947.e4. PubMed ID: 34600734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of single-inhaler extrafine triple therapy versus inhaled corticosteroid plus long-acting beta2 agonist in eastern Asian patients with COPD: the TRIVERSYTI randomised controlled trial.
    Zheng J; Baldi S; Zhao L; Li H; Lee KH; Singh D; Papi A; Grapin F; Guasconi A; Georges G
    Respir Res; 2021 Mar; 22(1):90. PubMed ID: 33757520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy And Safety Of Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (GFF MDI) Formulated Using Co-Suspension Delivery Technology In Chinese Patients With COPD.
    Chen R; Zhong N; Wang HY; Zhao L; Mei X; Qin Z; Huang J; Assam PN; Maes A; Siddiqui S; Martin UJ; Reisner C
    Int J Chron Obstruct Pulmon Dis; 2020; 15():43-56. PubMed ID: 32021143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Lung Function versus Monotherapies in GOLD Category A Patients with COPD: Pooled Data from the Phase III PINNACLE Studies.
    Martinez FJ; Rabe KF; Lipworth BJ; Arora S; Jenkins M; Martin UJ; Reisner C
    Int J Chron Obstruct Pulmon Dis; 2020; 15():99-106. PubMed ID: 32021148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized controlled trial of glycopyrrolate administered by metered dose inhaler in patients with uncontrolled asthma despite ICS/LABA treatment.
    Kerwin E; Dorinsky P; Patel M; Rossman K; Reisner C; Maes A; Darken P; Griffis D; Fjällbrant H
    J Asthma; 2022 Jul; 59(7):1420-1432. PubMed ID: 34338132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of nebulized formoterol as add-on therapy in COPD patients receiving maintenance tiotropium bromide: Results from a 6-week, randomized, placebo-controlled, clinical trial.
    Hanania NA; Boota A; Kerwin E; Tomlinson L; Denis-Mize K
    Drugs; 2009 Jun; 69(9):1205-16. PubMed ID: 19537837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of inhaled extrafine beclomethasone dipropionate in adults with asthma: a randomized, parallel-group, dose-ranging study (BEAM).
    Montanaro A; Weinstein S; Beaudot C; Scott SM; Georges G
    J Asthma; 2022 Jul; 59(7):1410-1419. PubMed ID: 34030555
    [No Abstract]   [Full Text] [Related]  

  • 17. A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with moderate-to-very severe chronic obstructive pulmonary disease.
    Reisner C; Fabbri LM; Kerwin EM; Fogarty C; Spangenthal S; Rabe KF; Ferguson GT; Martinez FJ; Donohue JF; Darken P; St Rose E; Orevillo C; Strom S; Fischer T; Golden M; Dwivedi S
    Respir Res; 2017 Jan; 18(1):8. PubMed ID: 28061907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.
    Keam SJ; Keating GM
    Treat Respir Med; 2004; 3(4):247-68. PubMed ID: 15350163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase IIb randomized, chronic-dosing, incomplete block, cross-over study of glycopyrronium, delivered via metered dose inhaler, compared with a placebo and an active control in patients with moderate-to-severe COPD.
    Kerwin EM; Spangenthal S; Kollar C; St Rose E; Reisner C
    Respir Res; 2018 Mar; 19(1):38. PubMed ID: 29506504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Randomized, Double-Blind, Double-Dummy Study of Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Relative to Umeclidinium/Vilanterol Dry Powder Inhaler in COPD.
    Maltais F; Ferguson GT; Feldman GJ; Deslee G; Bourdin A; Fjällbrant H; Siwek-Posłuszna A; Jenkins MA; Martin UJ
    Adv Ther; 2019 Sep; 36(9):2434-2449. PubMed ID: 31267366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.